According to Dr. William Hobbs, diseases with a significant unmet need like sickle cell disease require a strategy of serial innovation.

According to Dr. William Hobbs, the pharmaceutical industry has largely ignored sickle cell disease for a long time.

There has been a historical perception in the pharmaceutical industry that sickle cell disease is a difficult market to enter from a commercial and marketing standpoint.

Vertex Pharmaceuticals' R&D strategy for sickle cell disease involves investigating multiple different therapeutic approaches to treat the underlying causal biology of the disease.

Vertex Pharmaceuticals' internal R&D process involves aggressively pursuing scientific goals and constantly striving to out-innovate its own existing programs.

Dr. William Hobbs believes the large unmet need among millions of sickle cell disease patients worldwide makes developing treatments a compelling business opportunity, provided the approach is based o...